Verona Pharma Plc ADR (NASDAQ:VRNA) has a beta value of 0.23 and has seen 0.46 million shares traded in the recent trading session. The company, currently valued at $5.10B, closed the recent trade at $60.26 per share which meant it gained $1.72 on the day or 2.94% during that session. The VRNA stock price is -16.83% off its 52-week high price of $70.40 and 81.1% above the 52-week low of $11.39. If we look at the company’s 10-day average daily trading volume, we find that it stood at 1.01 million shares traded. The 3-month trading volume is 1.45 million shares.
The consensus among analysts is that Verona Pharma Plc ADR (VRNA) is Buy stock at the moment, with a recommendation rating of 1.00. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 0 out of 7 have rated it as a Hold, with 7 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -0.03.
Verona Pharma Plc ADR (NASDAQ:VRNA) trade information
Sporting 2.94% in the green today, the stock has traded in the red over the last five days, with the highest price hit on recent trading when the VRNA stock price touched $60.26 or saw a rise of 9.8%. Year-to-date, Verona Pharma Plc ADR shares have moved 29.76%, while the 5-day performance has seen it change -6.11%. Over the past 30 days, the shares of Verona Pharma Plc ADR (NASDAQ:VRNA) have changed -10.73%. Short interest in the company has seen 9.85 million shares shorted with days to cover at 6.25.
Wall Street analysts have a consensus price target for the stock at $75, which means that the shares’ value could jump 19.65% from the levels at last check today. The projected low price target is $74.0 while the price target rests at a high of $83.0. In that case, then, we find that the latest price level in today’s session is -37.74% off the targeted high while a plunge would see the stock gain -22.8% from the levels at last check today.
Verona Pharma Plc ADR (VRNA) estimates and forecasts
The company’s shares have gained 109.45% over the past 6 months. Revenue growth from the last financial year stood is estimated to be 626.15%.
8 analysts offering their estimates for the company have set an average revenue estimate of 41.47M for the current quarter. 8 have an estimated revenue figure of 53.02M for the next ending quarter. If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was 7.21% over the past 5 years.
VRNA Dividends
Verona Pharma Plc ADR is expected to release its next earnings report on 2025-Feb-26 this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Verona Pharma Plc ADR (NASDAQ:VRNA)’s Major holders
Insiders own 35.16% of the company shares, while shares held by institutions stand at 85.80% with a share float percentage of 132.32%. Investors are also buoyed by the number of investors in a company, with Verona Pharma Plc ADR having a total of 246.0 institutions that hold shares in the company. The top two institutional holders are FEDERATED HERMES, INC. with over 2.16 million shares worth more than $31.29 million. As of 2024-06-30, FEDERATED HERMES, INC. held 2.6806% of shares outstanding.
The other major institutional holder is RA CAPITAL MANAGEMENT, L.P., with the holding of over 7.63 million shares as of 2024-06-30. The firm’s total holdings are worth over $110.37 million and represent 1.1775% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are MUTUAL FUND SERIES TRUST-Eventide Gilead Fund and Federated Hermes Equity Funds-Federated Hermes Kaufmann Fund. As of Dec 31, 2024, the former fund manager holds about 2.31% shares in the company for having 1.89 shares of worth $113.45 million while later fund manager owns 1.24 shares of worth $74.17 million as of Oct 31, 2024, which makes it owner of about 1.51% of company’s outstanding stock.
